4-chloro-1,2-dihydrobenzopyrrolo<1,2,3-ef><1,5>benzodiazepin-7-one | 96014-93-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯二氮卓类
• 英文名称: 4-chloro-1,2-dihydrobenzopyrrolo<1,2,3-ef><1,5>benzodiazepin-7-one
• 英文别名: 4-chloro-1,2-dihydrobenzo[c]pyrrolo[1,2,3-ef][1,5]benzodiazepin-7-one；4-chloro-1,2-dihydrobenzo[c]pyrrolo(1,2,3-ef)[1,5]benzodiazepin-7-one；12-chloro-1,9-diazatetracyclo[8.6.1.02,7.014,17]heptadeca-2,4,6,10,12,14(17)-hexaen-8-one
• CAS: 96014-93-6
• 化学式: C₁₅H₁₁ClN₂O
• 分子量: 270.718
• InChiKey: WAACPRGFKHIKGC-UHFFFAOYSA-N

物化性质

• 熔点：
  252-255 °C
• 沸点：
  379.8±42.0 °C(Predicted)
• 密度：
  1.47±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  19
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  32.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-chloro-1,2-dihydrobenzopyrrolo<1,2,3-ef><1,5>benzodiazepin-7-one 在 2,3-二氯-5,6-二氰基-1,4-苯醌 作用下， 以 xylene 为溶剂， 反应 2.5h， 以54%的产率得到4-chlorobenzopyrrolo<1,2,3-ef><1,5>benzodiazepin-7-one
  参考文献：
  名称：

  四环苯并二氮杂.。4.新型苯并[ c ]吡咯并[1,2,3- ef ] [1,5]苯并二氮杂ring环体系及其具有潜在抗精神病活性的衍生物的合成

  摘要：

  描述了新型苯并[ c ]吡咯并[1,2,3- ef ] [1,5]苯并二氮杂ring环系统的合成。这是通过适当取代的（7-氨基吲哚-1-基）苯甲酰胺或苯甲酸环化来实现的。在四氯化钛的存在下，使所得的四环内酰胺与N-甲基哌嗪反应，以提供衍生物，并对其潜在的抗精神病活性进行了测试。

  DOI：

  10.1002/jhet.5570240620
• 作为产物：
  描述：

  2-(7-amino-5-chloro-2,3-dihydro-1H-indol-1-yl)benzamide 反应 1.5h， 以61%的产率得到4-chloro-1,2-dihydrobenzopyrrolo<1,2,3-ef><1,5>benzodiazepin-7-one
  参考文献：
  名称：

  四环苯并二氮杂.。4.新型苯并[ c ]吡咯并[1,2,3- ef ] [1,5]苯并二氮杂ring环体系及其具有潜在抗精神病活性的衍生物的合成

  摘要：

  描述了新型苯并[ c ]吡咯并[1,2,3- ef ] [1,5]苯并二氮杂ring环系统的合成。这是通过适当取代的（7-氨基吲哚-1-基）苯甲酰胺或苯甲酸环化来实现的。在四氯化钛的存在下，使所得的四环内酰胺与N-甲基哌嗪反应，以提供衍生物，并对其潜在的抗精神病活性进行了测试。

  DOI：

  10.1002/jhet.5570240620

文献信息

• Benzo[b]pyrrolo[3,2,1-jk][1,4]benzodiazepines having dopamine receptor
  申请人：Hoechst-Roussel Pharmaceuticals Inc.

  公开号：US04663453A1

  公开（公告）日：1987-05-05

  The invention relates to benzopyrrolobenzodiazepines and quinobenzodiazepines of the formula ##STR1## where X and Y may be the same or different and each is hydrogen, halogen, CF.sub.3, lower alkyl, lower alkoxy, lower alkylthio and lower alkylsulfonyl, p and q are independently 1 or 2; R.sub.1 is hydrogen when R.sub.2 is bonded to R.sub.3 to form a --(CH.sub.2).sub.m --CH.sub.2 -- group or a --CH.dbd.CH-- group; R.sub.3 is hydrogen when R.sub.1 is bonded to R.sub.2 to form a --(CH.sub.2).sub.m --CH.sub.2 -- group or a --CH.dbd.CH-- group; m is 1 or 2; R.sub.4 is NR.sub.5 R.sub.6 wherein R.sub.5 is hydrogen or lower alkyl and R.sub.6 is hydrogen, lower alkyl or a group of the formula (CH.sub.2).sub.n NR.sub.7 R.sub.8 wherein R.sub.7 and R.sub.8 are lower alkyl, and n is 2 or 3, ##STR2## wherein R.sub.9 is lower alkyl, ##STR3## wherein R.sub.10 is CH.sub.2 CH.sub.2 OH, lower alkyl, phenyl, phenyl substituted by halogen, CF.sub.3, lower alkyl, lower alkoxy or lower alkylthio, benzyl, benzyl in which the phenyl group is substituted by halogen, CF.sub.3, lower alkyl, lower alkoxy or lower alkylthio or CO.sub.2 R.sub.11 wherein R.sub.11 is lower alkyl, or a pharmaceutically acceptable acid salt thereof.

  该发明涉及苯并吡咯苯二氮杂环和喹诺苯二氮杂环，其化学式为##STR1##其中X和Y可以相同也可以不同，每个都是氢、卤素、CF.sub.3、低烷基、低烷氧基、低烷硫基和低烷基磺酰基，p和q独立地为1或2；R.sub.1为氢，当R.sub.2与R.sub.3连接形成--(CH.sub.2).sub.m --CH.sub.2 --基团或--CH.dbd.CH--基团时；R.sub.3为氢，当R.sub.1与R.sub.2连接形成--(CH.sub.2).sub.m --CH.sub.2 --基团或--CH.dbd.CH--基团时；m为1或2；R.sub.4为NR.sub.5 R.sub.6，其中R.sub.5为氢或低烷基，R.sub.6为氢、低烷基或(CH.sub.2).sub.n NR.sub.7 R.sub.8基团，其中R.sub.7和R.sub.8为低烷基，n为2或3，##STR2##其中R.sub.9为低烷基，##STR3##其中R.sub.10为CH.sub.2 CH.sub.2 OH、低烷基、苯基、被卤素、CF.sub.3、低烷基、低烷氧基或低烷硫基取代的苯基、苄基、苄基中苯基被卤素、CF.sub.3、低烷基、低烷氧基或低烷硫基取代或CO.sub.2 R.sub.11，其中R.sub.11为低烷基，或其药学上可接受的酸盐。
• Benzopyrrolobenzodiazepines and quinobenzodiazepines
  申请人：Hoechst-Roussel Pharmaceuticals Inc.

  公开号：US04723007A1

  公开（公告）日：1988-02-02

  The invention relates to benzopyrrolobenzodiazepines and quinobenzodiazepines of the formula ##STR1## where X and Y may be the same or different and each is hydrogen, halogen, CF.sub.3, lower alkyl, lower alkoxy, lower alkylthio and lower alkylsulfonyl, p and q are independently 1 or 2; R.sub.1 is hydrogen when R.sub.2 is bonded to R.sub.3 to form a --(CH.sub.2).sub.m --CH.sub.2 -- group or a --CH.dbd.CH-- group; R.sub.3 is hydrogen when R.sub.1 is bonded to R.sub.2 to form a --(CH.sub.2).sub.m --CH.sub.2 -- group or a --CH.dbd.CH-- group; m is 1 or 2; R.sub.4 is NR.sub.5 R.sub.6 wherein R.sub.5 is hydrogen or lower alkyl and R.sub.6 is hydrogen, lower alkyl or a group of the formula (CH.sub.2).sub.n NR.sub.7 R.sub.8 wherein R.sub.7 and R.sub.8 are lower alkyl, and n is 2 or 3, ##STR2## wherein R.sub.9 is lower alkyl, ##STR3## wherein R.sub.10 is CH.sub.2 CH.sub.2 OH, lower alkyl, phenyl, phenyl substituted by halogen, CF.sub.3, lower alkyl, lower alkoxy or lower alkylthio, benzyl, benzyl in which the phenyl group is substituted by halogen, CF.sub.3, lower alkyl, lower alkoxy or lower alkylthio or CO.sub.2 R.sub.11 wherein R.sub.11 is lower alkyl, or a pharmaceutically acceptable acid salt thereof.

  本发明涉及公式##STR1##中的苯并吡咯苯并二氮杂环和喹诺苯并二氮杂环，其中X和Y可以相同也可以不同，每个都是氢、卤素、CF.sub.3、低烷基、低烷氧基、低烷硫基和低烷基磺酰基，p和q独立地为1或2; 当R.sub.2与R.sub.3结合形成--(CH.sub.2).sub.m --CH.sub.2--基团或--CH.dbd.CH--基团时，R.sub.1为氢; 当R.sub.1与R.sub.2结合形成--(CH.sub.2).sub.m --CH.sub.2--基团或--CH.dbd.CH--基团时，R.sub.3为氢; m为1或2; R.sub.4为NR.sub.5R.sub.6，其中R.sub.5为氢或低烷基，R.sub.6为氢、低烷基或(CH.sub.2).sub.nNR.sub.7R.sub.8的基团，其中R.sub.7和R.sub.8为低烷基，n为2或3，##STR2##其中R.sub.9为低烷基，##STR3##其中R.sub.10为CH.sub.2CH.sub.2OH、低烷基、苯基、被卤素、CF.sub.3、低烷基氧基或低烷硫基取代的苯基、苄基、苄基中苯基被卤素、CF.sub.3、低烷基氧基或低烷硫基取代或CO.sub.2R.sub.11，其中R.sub.11为低烷基，或其药学上可接受的酸盐。
• Benzopyrrolobenzodiazepines and quinobenzodiazepines useful for the
  申请人：Hoechst-Roussel Pharmaceuticals Inc.

  公开号：US04761412A1

  公开（公告）日：1988-08-02

  The invention relates to benzopyrrolobenzodiazepines and quinobenzodiazepines of the formula ##STR1## where X and Y may be the same or different and each is hydrogen, halogen, CF.sub.3, lower alkyl, lower alkoxy, lower alkylthio and lower alkylsulfonyl, p and q are independently 1 or 2; R.sub.1 is hydrogen when R.sub.2 is bonded to R.sub.3 to form a --(CH.sub.2).sub.m --CH.sub.2 -- group or a --CH.dbd.CH-- group; R.sub.3 is hydrogen when R.sub.1 is bonded to R.sub.2 to form a --(CH.sub.2).sub.m --CH.sub.2 -- group or a --CH.dbd.CH-- group; m is 1 or 2; R.sub.4 is NR.sub.5 R.sub.6 wherein R.sub.5 is hydrogen or lower alkyl and R.sub.6 is hydrogen, lower alkyl or a group of the formula (CH.sub.2).sub.n NR.sub.7 R.sub.8 wherein R.sub.7 and R.sub.8 are lower alkyl, and n is 2 or 3, ##STR2## wherein R.sub.9 is lower alkyl, ##STR3## wherein R.sub.10 is CH.sub.2 CH.sub.2 OH, lower alkyl, phenyl, phenyl substituted by halogen, CF.sub.3, lower alkyl, lower alkoxy or lower alkylthio, benzyl, benzyl in which the phenyl group is substituted by halogen, CF.sub.3, lower alkyl, lower alkoxy or lower alkylthio or CO.sub.2 R.sub.11 wherein R.sub.11 is lower alkyl, or a pharmaceutically acceptable acid salt thereof.

  本发明涉及式子##STR1##的苯并吡咯苯并二氮杂环己烷和喹诺苯并二氮杂环己烷，其中X和Y可以相同或不同，每个都是氢，卤素，CF.sub.3，低烷基，低烷氧基，低烷硫基和低烷基磺酰基，p和q独立地为1或2;当R.sub.2与R.sub.3连接形成--(CH.sub.2).sub.m --CH.sub.2--基团或--CH.dbd.CH--基团时，R.sub.1为氢;当R.sub.1与R.sub.2连接形成--(CH.sub.2).sub.m --CH.sub.2--基团或--CH.dbd.CH--基团时，R.sub.3为氢; m为1或2; R.sub.4为NR.sub.5R.sub.6，其中R.sub.5为氢或低烷基，R.sub.6为氢，低烷基或(CH.sub.2).sub.n NR.sub.7R.sub.8基团，其中R.sub.7和R.sub.8为低烷基，n为2或3，##STR2##其中R.sub.9为低烷基，##STR3##其中R.sub.10为CH.sub.2CH.sub.2OH，低烷基，苯基，被卤素，CF.sub.3，低烷基，低烷氧基或低烷硫基取代的苯基，苄基，被卤素，CF.sub.3，低烷基，低烷氧基或低烷硫基取代的苄基或CO.sub.2R.sub.11，其中R.sub.11为低烷基，或其药学上可接受的酸盐。
• Dihydrobenzopyrrolobenzodiazepines useful for treating pyschoses
  申请人：Hoechst-Roussel Pharmaceuticals Inc.

  公开号：US04761411A1

  公开（公告）日：1988-08-02

  The invention relates to dihydrobenzopyrrolobenzodiazepines of the formula ##STR1## where X and Y may be the same or different and each is hydrogen, halogen, CF.sub.3, lower alkyl, lower alkoxy, lower alkylthio and lower alkylsulfonyl; R.sub.1 is hydrogen when R.sub.2 is bonded to R.sub.3 to form a --CH.sub.2 CH.sub.2 -- group; and R.sub.3 is hydrogen when R.sub.1 is bonded to R.sub.2 to form a --CH.sub.2 CH.sub.2 -- group and the pharmaceutically acceptable acid addition salts thereof.

  本发明涉及公式为##STR1##的二氢苯并吡咯苯并二氮杂环化合物，其中X和Y可能相同或不同，且每个都是氢、卤素、CF.sub.3、低烷基、低烷氧基、低烷硫基和低烷基磺酰基；当R.sub.2与R.sub.3结合形成--CH.sub.2 CH.sub.2 --基团时，R.sub.1为氢；当R.sub.1与R.sub.2结合形成--CH.sub.2 CH.sub.2 --基团时，R.sub.3为氢。还包括其药学上可接受的酸盐。
• Dibenzodiazepin derivatives, a process for their preparation and their use as medicaments
  申请人：HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED

  公开号：EP0129692A2

  公开（公告）日：1985-01-02

  The invention relates to dihydrobenzopyrrolobenzodiazepines of the formula where X and Y may be the same or different and each is hydrogen, halogen, CF., lower alkoxy, lower alkylthio and lower alkylsulfonyl; R, is hydrogen when R2 is bonded to R3 to form a -(CH2)m-CH2-group or a -CH=CH-group; R3 is hydrogen when R, is bonded to R. to form a -(CH2)m-CH2- group or a -CH-CH- group; and R4 is NR5R6 wherein R. is hydrogen or lower alkyl and R6 is hydrogen, lower alkyl or a group of the formula (CH2)nNR7R8 wherein R7 and R. are lower alkyl, m is 1 or 2 and n is 2 or 3, wherein R. is lower alkyl, or wherein R10 is lower alkyl, phenyl, phenyl substituted by halogen, CF3, lower alkyl, lower alkoxy or lower alkylthio, benzyl, benzyl in which the phenyl group is substituted by halogen, CF3, lower alkyl, lower alkoxy or lower alkylthio or CO2R11, wherein R11 is lower alkyl, or a pharmaceutically acceptable acid salt thereof.

  本发明涉及式如下的二氢吡咯并二氮杂卓 式中 X 和 Y 可以相同或不同，各自为氢、卤素、CF、当 R2 与 R3 键合形成-(CH2)m-CH2-基团或-CH=CH-基团时，R3 为氢；当 R2 与 R3 键合形成-(CH2)m-CH2-基团或-CH=CH-基团时，R3 为氢。和 R4 是 NR5R6，其中 R. 是氢或低级烷基，R6 是氢、低级烷基或式 (CH2)nNR7R8 的基团，其中 R7 和 R. 是低级烷基，m 是 1 或 2，n 是 2 或 3、 其中 R. 为低级烷基 或 其中 R10 为低级烷基、苯基、被卤素、CF3、低级烷基、低级烷氧基或低级烷硫基取代的苯基、苄基、苯基被卤素、CF3、低级烷基、低级烷氧基或低级烷硫基取代的苄基或 CO2R11（其中 R11 为低级烷基）或其药学上可接受的酸盐。